Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
This article is part of Med Tech Outlook's Innovation Insights series featuring expert contributions nominated by our subscribers and reviewed by our editorial team.
Thanks to the collaboration with these partners, EUKON has introduced a new concept of innovation and safety in the MedTech sector, in fact, EUKON boasts the brilliance of around 12,000 peripheral stent procedures and guarantees a presence in over 150 Italian laboratories. Today, EUKON is the winning choice in Italy for both start-ups and multinationals that want to entrust the sales process, the launch of a new product or the management of the entire commercial portfolio to an efficient, flexible and dynamic structure. Proof of this is the launch of the pVAD iVAC 2L, a medical device that has been on the Italian market for about two years and is enjoying huge success throughout Italy. Thanks to its revolutionary technology, positioned in the left ventricular cavity via the femoral artery, the iVAC provides hemodynamic support during revascularization interventions in cases of heart attack and cardiogenic shock and in high-risk patients. In the MedTech sector, change is a process that cannot be avoided; on the contrary, it provides great opportunities for innovations, and for EUKON, innovations will always be the best fuel for ensuring patient safety while respecting the world around it!
At EUKON, we believe innovation and responsibility go hand in hand. We're constantly seeking new technologies to improve patient care while minimizing our environmental impact and fostering a diverse and inclusive workplace.
The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
